Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label

Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label

Source: 
Endpoints
snippet: 

Blueprint Medicines presented the full dataset for its drug Ayvakit at a medical conference over the weekend as it heads towards an FDA decision in May. Blueprint is hoping to expand Ayvakit’s label into a less advanced form of systemic mastocytosis, a rare disease in which too many mast cells, a type of white blood cell, build up in the body.